Rapacuronium

From Wikipedia, the free encyclopedia

This article or section relies largely or entirely upon a single source. Please help improve this article by introducing appropriate citations of additional sources.

Rapacuronium bromide
Systematic (IUPAC) name
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17S)- 3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16- (1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin- 1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro- 1H-cyclopenta[a]phenanthren-17-yl]propanoate
Identifiers
CAS number	156137-99-4
ATC code	?
PubChem	5311398
Chemical data
Formula	C37H61N2O4+
Mol. mass	597.891 g/mol
Pharmacokinetic data
Bioavailability	Not applicable
Protein binding	Variable
Metabolism	Hydrolyzed to active metabolites CYP system not involved
Half life	141 minutes (mean)
Excretion	Renal and fecal
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	Withdrawn (U.S)
Routes	Intravenous

Rapacuronium bromide (trade name Raplon, Organon) is a rapidly acting, non-depolarizing neuromuscular blocker used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent, it does not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm, it was withdrawn from the United States market by the manufacturer on March 27, 2001.^[1]

[edit] References